Top Clicks This Month

2,2,3,3-Tetrafluoro-6-nitrilobenzodioxene - CAS 215732-94-8

Quick Inquiry

Name:
* Email:
* Service & Products of Interest:
* Quantity:
* Verification code:
Please input "bocsci" as verification code.
Category
Main Product
Product Name
2,2,3,3-Tetrafluoro-6-nitrilobenzodioxene
Catalog Number
215732-94-8
Synonyms
2,2,3,3-Tetrafluoro-6-nitrilobenzodioxene;2,2,3,3-tetrafluoro-1,4-benzodioxine-6-carbonitrile;AC1MCR3T;SCHEMBL623724;QPYMMYGNDXPHIU-UHFFFAOYSA-N;PC4758
CAS Number
215732-94-8
Molecular Weight
233.12
Molecular Formula
C9H3F4NO2
COA
Inquire
MSDS
Inquire
Canonical SMILES
C1=CC2=C(C=C1C#N)OC(C(O2)(F)F)(F)F
InChI
InChI=1S/C9H3F4NO2/c10-8(11)9(12,13)16-7-3-5(4-14)1-2-6(7)15-8/h1-3H
InChIKey
QPYMMYGNDXPHIU-UHFFFAOYSA-N
Structure
CAS 215732-94-8 2,2,3,3-Tetrafluoro-6-nitrilobenzodioxene
Specification
Purity
95%
Reference Reading
1.Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study.
Beesley VL1, Wockner LF2, O'Rourke P2, Janda M3, Goldstein D4,5, Gooden H6, Merrett ND7,8, O'Connell DL9, Rowlands IJ10, Wyld DK11,12, Neale RE2. Support Care Cancer. 2016 Apr 16. [Epub ahead of print]
PURPOSE: This study aims to determine if the supportive care needs of people with pancreatic cancer change over time and identify the factors associated with current and future unmet needs.
2.Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Koh K1, Ogawa C2,3, Okamoto Y4, Kudo K5,6, Inagaki J7, Morimoto T8, Mizukami H9, Ecstein-Fraisse E9, Kikuta A10. Int J Hematol. 2016 Apr 16. [Epub ahead of print]
A phase 1 study was conducted to evaluate the safety, pharmacokinetics (PK), efficacy and pharmacogenetic characteristics of clofarabine in seven Japanese pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Patients in Cohort 1 received clofarabine 30 mg/m2/day for 5 days, followed by 52 mg/m2/day for 5 days in subsequent cycles. Cohort 2 patients were consistently treated with 52 mg/m2/day for 5 days. No more than six cycles were performed. Every patient had at least one ≥Grade 3 adverse event (AE). AEs (≥Grade 3) related to clofarabine were anaemia, neutropenia, febrile neutropenia, thrombocytopenia, alanine aminotransferase increased, aspartate aminotransferase increased, haemoglobin decreased, and platelet (PLT) count decreased. C max and AUC of clofarabine increased in a dose-dependent fashion, but its elimination half-life (T 1/2) did not appear to be dependent on dose or duration of treatment. Clofarabine at 52 mg/m2/day shows similarly tolerable safety and PK profiles compared to those in previous studies.
3.Use of PET tracers for parathyroid localization: a systematic review and meta-analysis.
Kluijfhout WP1,2, Pasternak JD3, Drake FT4, Beninato T4, Gosnell JE4, Shen WT4, Duh QY4, Allen IE5, Vriens MR6, de Keizer B7, Pampaloni MH8, Suh I4. Langenbecks Arch Surg. 2016 Apr 16. [Epub ahead of print]
PURPOSE: The great spatial and temporal resolution of positron emission tomography might provide the answer for patients with primary hyperparathyroidism (pHPT) and non-localized parathyroid glands. We performed a systematic review of the evidence regarding all investigated tracers.
4.Metastasis to the lymph nodes along the proper hepatic artery from adenocarcinoma of the stomach.
Kumagai K1, Hiki N2, Nunobe S1, Irino T1, Ida S1, Ohashi M1, Yamaguchi T1, Sano T1. Langenbecks Arch Surg. 2016 Apr 16. [Epub ahead of print]
PURPOSE: The study sought the significance of resecting lymph nodes along the proper hepatic artery (station 12a) in gastric cancer surgery and the possibility of predicting station 12a involvement from clinicopathological factors or metastatic status in other regional lymph nodes of the stomach.
2005 - BOC Sciences | All rights reserved
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE
BOCSciences
X CLOSE